List of Excipients in Branded Drug AROMASIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	AROMASIN	exemestane	0009-7663	CELLULOSE, MICROCRYSTALLINE
Pharmacia & Upjohn Company LLC	AROMASIN	exemestane	0009-7663	CROSPOVIDONE
Pharmacia & Upjohn Company LLC	AROMASIN	exemestane	0009-7663	HYPROMELLOSE
Pharmacia & Upjohn Company LLC	AROMASIN	exemestane	0009-7663	MAGNESIUM CARBONATE

Exemestane Excipient Strategy and Commercial Opportunities for Aromasin

Last updated: August 4, 2026

Aromasin is the branded oral exemestane product developed by Pharmacia and approved by the FDA in 1999 for postmenopausal women with estrogen-receptor-positive early breast cancer after tamoxifen and for advanced breast cancer after progression on tamoxifen [1]. Its commercial formulation is a conventional immediate-release, film-coated tablet containing 25 mg of exemestane. The formulation uses common direct-compression and film-coating excipients, creating opportunities for lower-cost generic supply, differentiated oral products, regional manufacturing, and excipient optimization rather than complex drug-delivery competition.

The main technical priorities are dissolution consistency, content uniformity at a low drug load, control of tablet disintegration, coating robustness, excipient compatibility, and preservation of exemestane exposure under the labeled fed-state administration.

What excipients are used in Aromasin tablets?

Aromasin contains a conventional solid oral excipient system. FDA labeling identifies the core excipients as mannitol, microcrystalline cellulose, crospovidone, polysorbate 80, colloidal silicon dioxide, and magnesium stearate. The film coating contains standard coating materials, including hypromellose, titanium dioxide, talc, and colorants [1,2].

Formulation function	Aromasin excipient or excipient class	Commercial purpose
Diluent	Mannitol	Adds tablet bulk and supports a low-dose tablet matrix
Binder and compressibility aid	Microcrystalline cellulose	Provides compactibility and mechanical strength
Superdisintegrant	Crospovidone	Promotes rapid tablet breakup
Wetting or solubilization aid	Polysorbate 80	Supports wetting of the poorly water-soluble active ingredient
Glidant	Colloidal silicon dioxide	Improves powder flow and blend uniformity
Lubricant	Magnesium stearate	Reduces tablet ejection friction
Film former	Hypromellose	Provides the protective tablet coating
Opacifier and pigment	Titanium dioxide and iron oxide or related colorants	Controls appearance and light protection
Anti-adherent or coating aid	Talc	Improves coating processing and surface properties

The exact quantitative composition is proprietary. Generic manufacturers must reproduce the product's pharmaceutical performance, not necessarily its precise excipient percentages.

How does the Aromasin formulation work?

Exemestane is a steroidal aromatase inactivator with low aqueous solubility. The formulation therefore depends on rapid wetting, tablet disintegration, and adequate dispersion of the active ingredient rather than on a sophisticated sustained-release system.

Immediate-release tablet design

Microcrystalline cellulose and mannitol provide the tablet mass needed to manufacture a 25 mg dosage unit. Crospovidone offsets the risk that a compact tablet will resist water penetration. Colloidal silicon dioxide improves powder handling, while magnesium stearate supports high-speed tableting.

Polysorbate 80 is strategically important because it can improve wetting of a hydrophobic active ingredient. Its concentration must be controlled because excess surfactant can alter dissolution, affect blend behavior, and create stability or packaging issues.

The formulation is taken after a meal. The FDA label reports increased exemestane exposure when the drug is administered with food, supporting a product-development focus on fed-state performance and consistent patient instructions [1].

Film coating

The film coat supports identification, handling, swallowability, and protection from abrasion. It can also reduce variability caused by surface chipping and tablet dust. A generic manufacturer may use a different approved coating system if the finished product matches relevant quality, stability, appearance, and bioequivalence requirements.

What formulation patents protect Aromasin?

Aromasin's original U.S. exclusivity was based primarily on patents covering exemestane and its use as an aromatase inhibitor. The principal commercial barrier has expired, and exemestane tablets are available from multiple generic manufacturers.

The current commercial opportunity is not based on extending the original Aromasin tablet patent. It is based on creating a regulatory and manufacturing advantage through:

• improved dissolution or bioavailability;
• lower tablet weight;
• reduced coating and packaging cost;
• excipient substitution;
• alternative tablet manufacturing;
• fixed-dose combinations;
• adherence-oriented packaging;
• geographic supply and licensing arrangements.

A new formulation patent would need to claim a genuine technical distinction, such as a specific composition, manufacturing process, particle-size distribution, solid form, or demonstrated stability advantage. A broad claim covering ordinary use of mannitol, microcrystalline cellulose, crospovidone, and magnesium stearate would face significant validity and obviousness pressure because those excipients are standard pharmaceutical materials.

When did Aromasin lose exclusivity?

Aromasin lost meaningful U.S. small-molecule exclusivity after expiration of its core patent protection and the launch of generic exemestane products. FDA records identify exemestane tablets as an approved generic product category [2,3].

Milestone	Approximate timing
FDA approval of Aromasin	December 1999
Original branded indication	Early breast cancer after tamoxifen
Advanced breast cancer indication	1999-2000 period
Core small-molecule patent protection	Expired before broad generic availability
Generic exemestane availability	From 2012 in the U.S. market
Current market status	Mature generic oral solid market

Exact generic launch timing varied by manufacturer and litigation outcome. Current Orange Book review should be performed against the latest FDA edition because listed patents, therapeutic-equivalence codes, and marketing status can change over time [3].

What is the Orange Book status of Aromasin and exemestane?

Aromasin is an approved reference product for exemestane tablets. Generic exemestane tablets are generally approved through abbreviated new drug applications using Aromasin as the reference listed drug.

The principal Orange Book issues are:

1. Whether a product is listed as the reference listed drug or an ANDA product.
2. Whether the product has a therapeutic-equivalence code.
3. Whether any patent information remains listed for the reference product.
4. Whether a generic applicant submitted a Paragraph IV certification against a listed patent.
5. Whether pediatric exclusivity or other regulatory exclusivity affects approval timing.

For a mature product such as exemestane, the relevant commercial assessment is usually product quality, cost, supply reliability, and channel access rather than a remaining branded patent barrier.

Which companies are challenging Aromasin through generic competition?

Generic competition has come from manufacturers of exemestane tablets approved through the ANDA pathway. The competitive field has included large generic companies and regional suppliers, with availability varying by country and procurement channel.

The main competitive dimensions are:

• FDA-approved 25 mg tablet status;
• therapeutic equivalence;
• manufacturing-site reliability;
• API sourcing;
• contract manufacturing capacity;
• ability to supply oncology distributors;
• reimbursement and formulary positioning;
• shortage history;
• packaging configurations.

Because exemestane is an oral oncology product with a relatively narrow therapeutic use, supply continuity can be more valuable than marginal tablet-price reductions for hospitals and specialty distributors.

What excipient substitutions create the best generic opportunities?

The highest-value substitutions are those that preserve performance while reducing supply risk or manufacturing cost.

Mannitol versus lactose or other fillers

Mannitol supports a low-hygroscopicity formulation and may provide favorable mouthfeel. Lactose, dibasic calcium phosphate, or additional microcrystalline cellulose could reduce cost in some markets, but each substitution changes compaction, moisture behavior, disintegration, and dissolution. A formulation change would require comparative development and regulatory bridging.

Crospovidone versus croscarmellose sodium

Both are established superdisintegrants. Crospovidone can support rapid wicking and breakup, while croscarmellose sodium may provide strong swelling. The correct choice depends on tablet hardness, particle size, compression force, and dissolution performance.

Polysorbate 80 versus alternative wetting systems

A generic developer could evaluate sodium lauryl sulfate, poloxamer, or a self-emulsifying approach. The commercial advantage would be meaningful only if the alternative improves dissolution, reduces impurity risk, or solves a supply problem. Polysorbate 80 is widely available, so substitution alone is unlikely to create durable differentiation.

Magnesium stearate versus alternative lubricants

Sodium stearyl fumarate or other lubricants can reduce hydrophobic over-lubrication effects. The change may improve dissolution or reduce sensitivity to blending time. It also creates a new control strategy for tablet ejection, hardness, and scale-up.

Film-coating systems

Aqueous hypromellose systems are generally suitable for a conventional tablet. A coater may obtain cost savings through a ready-to-use premix, lower coating weight, shorter drying time, or regional colorant sourcing. The opportunity is operational rather than strongly patent-based.

How should an excipient strategy address bioequivalence?

For an immediate-release exemestane tablet, the development program should establish:

• comparative dissolution across multiple pH conditions;
• fed and fasted pharmacokinetic performance;
• assay and content uniformity;
• disintegration time;
• impurity and degradation-product control;
• physical stability under accelerated and long-term conditions;
• compatibility between exemestane and each excipient;
• robustness against lubricant level and blending-time variation.

The fed-state label is commercially significant. A formulation that reduces food-related exposure variability could support a differentiated development program, but it would need clinical evidence and an appropriate regulatory pathway. A simple excipient change is unlikely to justify a new indication or premium price without a measurable clinical or pharmacokinetic benefit.

What manufacturing and intellectual-property barriers affect exemestane?

The manufacturing barriers are moderate rather than technically extreme. Exemestane is a small-molecule API and the finished product is a conventional tablet. Key barriers include:

• consistent API particle size;
• control of steroid-related impurities;
• low-dose blend uniformity;
• reliable wetting and dissolution;
• tablet capping or sticking during compression;
• coating color consistency;
• protection from moisture and light;
• qualified API and excipient suppliers;
• regulatory comparability after site or material changes.

The strongest defensible IP positions would likely relate to a specific formulation or process with demonstrated performance. Examples include a particle-engineered exemestane composition, a high-solubility dispersion, a robust low-weight tablet, a stable fixed-dose combination, or a manufacturing method that reduces impurity formation.

What commercial opportunities exist beyond generic Aromasin?

Cost-optimized generic supply

The most immediate opportunity is a reliable, low-cost 25 mg generic tablet. Value comes from procurement access, API economics, and manufacturing utilization.

Emerging-market supply

Countries with limited access to endocrine therapy may support regional partnerships, local packaging, or licensed manufacturing. Excipients with multiple qualified suppliers are preferable because they reduce registration and supply-chain risk.

Fixed-dose combinations

Exemestane could be evaluated in combinations with medicines used in breast cancer treatment or supportive care. These products face substantial clinical, regulatory, and intellectual-property requirements. A combination is more commercially credible when it improves adherence or reduces pill burden.

Adherence packaging

Calendar blister packs, synchronized refill programs, and patient-specific packaging may support specialty-pharmacy contracts. These improvements are more likely to produce commercial differentiation than a minor change in tablet excipients.

Modified-release or enhanced-solubility products

A controlled-release product would require a new clinical and regulatory strategy and may not offer a clear benefit because Aromasin is dosed once daily. Enhanced-solubility systems could be more practical if they reduce food dependence or improve exposure consistency.

Contract development and manufacturing

Companies with oncology-tablet capacity can offer exemestane development, scale-up, packaging, and regional registration services. The value proposition is strongest where sponsors need a second source or where existing suppliers have limited capacity.

How strong is the Aromasin patent estate today?

The original Aromasin patent estate has limited ability to block ordinary generic exemestane tablets because the core commercial protection has expired. Patent strength for a new entrant depends on the claimed improvement.

Strategy	Patent strength	Commercial attractiveness
Conventional 25 mg tablet with standard excipients	Low	High for cost-based generic supply
Novel excipient ratio with improved dissolution	Moderate if data-supported	Moderate
Enhanced-solubility formulation	Moderate to high	Moderate, subject to clinical value
Fixed-dose combination	Moderate to high	Potentially high but development-intensive
Packaging and adherence system	Low to moderate	Moderate in specialty channels
New method of use	Potentially high	Depends on clinical differentiation
Novel manufacturing process	Moderate	High if it reduces cost or impurity burden

What generic launch risks exist for exemestane?

Generic launch risks are concentrated in regulatory execution and supply economics:

1. Failure to match dissolution or pharmacokinetic exposure.
2. Variability in low-dose blend uniformity.
3. API shortages or dependence on a single supplier.
4. Excipient changes that alter tablet performance.
5. Excessive competition that compresses margins.
6. Hospital and pharmacy preference for established suppliers.
7. Limited market size relative to registration and validation costs.
8. Product withdrawal risk after manufacturing-site changes.

Biosimilar risk is not relevant to Aromasin because exemestane is a chemically synthesized small molecule, not a biologic. The competitive threat is generic substitution, not biosimilar interchangeability.

What patent litigation and Paragraph IV risks affect exemestane?

Paragraph IV risk was most relevant when generic applicants challenged still-listed Aromasin patents before broad generic entry. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed. Such certifications can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework [4].

For current commercial planning, the important question is whether any later formulation or method-of-use patent remains listed and enforceable against the specific product design. A conventional generic using the established 25 mg immediate-release profile generally faces lower patent risk than a novel combination or modified-release product, although regulatory and freedom-to-operate review remains essential.

How does Aromasin compare with other aromatase inhibitors?

Product	Active ingredient	Form	Main formulation profile	Competitive position
Aromasin	Exemestane	25 mg tablet	Conventional immediate-release tablet	Mature branded and generic market
Arimidex	Anastrozole	1 mg tablet	Conventional immediate-release tablet	Mature generic market
Femara	Letrozole	2.5 mg tablet	Conventional immediate-release tablet	Mature generic market

Exemestane has a steroidal mechanism, while anastrozole and letrozole are nonsteroidal aromatase inhibitors. From an excipient and manufacturing perspective, all three are suitable for conventional generic oral solid development. Commercial differentiation is more likely to arise from supply reliability, patient support, combination products, or documented tolerability and adherence benefits than from basic tablet composition.

Key Takeaways

• Aromasin is a 25 mg immediate-release exemestane tablet with a conventional excipient platform.
• The core formulation uses mannitol, microcrystalline cellulose, crospovidone, polysorbate 80, colloidal silicon dioxide, magnesium stearate, and standard film-coating materials.
• The original branded patent barrier has expired, and generic competition is established.
• The strongest near-term opportunity is cost-efficient, reliable generic supply.
• Excipient substitution can reduce cost or supply risk, but changes must preserve dissolution, bioequivalence, stability, and content uniformity.
• New formulation patents require a measurable technical advantage because the underlying excipient classes are routine.
• Biosimilar risk does not apply. Generic substitution is the relevant competitive threat.
• Higher-value opportunities include enhanced-solubility products, fixed-dose combinations, adherence packaging, and regional licensing.
• Commercial returns depend heavily on API sourcing, manufacturing scale, procurement access, and supply continuity.

Frequently Asked Questions

Can lactose replace mannitol in an exemestane tablet?

Potentially, but the substitution would require formulation development because lactose changes compressibility, moisture behavior, dissolution, and compatibility risk.

Is polysorbate 80 necessary in generic exemestane?

Not necessarily. A generic can use another wetting or solubilizing system if the finished product meets regulatory performance requirements.

Does Aromasin have a biosimilar pathway?

No. Exemestane is a chemically synthesized small molecule and is generally developed through the generic ANDA pathway rather than a biosimilar pathway.

Can a new exemestane formulation receive a new patent?

Yes, if it claims a novel and non-obvious formulation, process, solid form, combination, or clinically meaningful use supported by technical evidence.

Is a 25 mg exemestane tablet commercially attractive for a new manufacturer?

It can be attractive where the manufacturer has low-cost API access, qualified oncology-tablet capacity, reliable supply, and a route to pharmacy, hospital, or government procurement contracts.

References

1. U.S. Food and Drug Administration. (2019). Aromasin (exemestane) tablets prescribing information. FDA.
2. National Library of Medicine. (2024). DailyMed: Aromasin and exemestane tablet labeling. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
4. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.